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UBE3A is a HECT domain E3 ubiquitin ligase whose dysfunc-
tion is linked to autism, Angelman syndrome, and cancer.
Recently, we characterized a de novo autism-linked UBE3A
mutant (UBE3AT485A) that disrupts phosphorylation control of
UBE3A activity. Through quantitative proteomics and reporter
assays, we found that the UBE3AT485A protein ubiquitinates
multiple proteasome subunits, reduces proteasome subunit
abundance and activity, stabilizes nuclear -catenin, and stim-
ulates canonical Wnt signaling more effectively than wild-type
UBE3A. We also found that UBE3AT485A activates Wnt signal-
ing to a greater extent in cells with low levels of ongoing Wnt
signaling, suggesting that cells with low basal Wnt activity are
particularly vulnerable to UBE3AT485A mutation. Ligase-dead
UBE3A did not stimulateWnt pathway activation. Overexpres-
sion of several proteasome subunits reversed the effect of
UBE3AT485A onWnt signaling. We also observed that subunits
that interact with UBE3A and affect Wnt signaling are located
along one side of the 19S regulatory particle, indicating a previ-
ously unrecognized spatial organization to the proteasome.
Altogether, our findings indicate thatUBE3A regulatesWnt sig-
naling in a cell context-dependent manner and that an autism-
linked mutation exacerbates these signaling effects. Our study
has broad implications for human disorders associated with
UBE3A gain or loss of function and suggests that dysfunctional
UBE3A might affect additional proteins and pathways that are
sensitive to proteasome activity.
Loss of UBE3A causes a debilitating neurodevelopmental
disorder called Angelman syndrome (1–3), whereas excess
UBE3A, through gene duplication or gain-of-function muta-
tion, increases the risk for autism (4–7). Moreover, ectopic
activation of UBE3A (also known as E6AP), via the human pap-
illomavirus E6 oncoprotein, contributes to cervical cancers (8).
UBE3A is an E3 ubiquitin ligase that targets several substrate
proteins, including itself, for proteasomal degradation (9).
Althoughmuch has been learned from studying postnatal func-
tions for UBE3A in mature neurons (10–13), precisely how
ubiquitination of these proteins, or other yet to be identified
substrates, affects brain development is largely unclear. Here,
we sought to gain new insights into developmental functions
for UBE3A by exploring a novel connection amongUBE3A, the
proteasome, and the Wnt signaling pathway.
Wnt signaling is a principal determinant of cell fate and pro-
liferation during development. Abnormal Wnt signaling is
implicated in autism pathogenesis (14–17), and Wnt signaling
is dysregulated in other diseases, including cancer (18, 19).
Induction of the canonicalWnt pathway centers on the dynam-
ics of -catenin degradation by the proteasome. In the absence
ofWnt ligand, a complex of cytosolic proteins, referred to as the
destruction complex, sequentially phosphorylates andubiquiti-
nates -catenin, resulting in its proteasomal degradation (Fig.
1) (20, 21). Conversely, the presence ofWnt induces the forma-
tion of a Frizzled receptor and low-density lipoprotein recep-
tor-related protein co-receptor complex (22). This stabilizes
-catenin and allows its translocation to the nucleus where
-catenin functions as a transcriptional co-activator with
members of the T cell factor/lymphoid enhancer factor family
of transcription factors (Fig. 1).
It is well known that UBE3A reversibly associates with the
proteasome and impacts its processivity (23–27). Moreover,
proteasome subunits and proteasome-associated proteins
physically interact with and are ubiquitinated by UBE3A (28–
34). The relevance of these UBE3A substrates to nervous sys-
tem development is largely unclear with the notable exception
of UCHL5 whose deletion leads to disorganized brain develop-
ment (35) and PSMD4 (S5A/RPN10), which promotes dendrite
development (36). It is also well known that proteasome in-
hibitors, such as MG-132, block proteasomal processing of
-catenin and potently activate Wnt signaling (37, 38). As part
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of a genome-wide small interfering RNA screen, we found that
Wnt pathway activation is highly sensitive to knockdown of
specific proteasomal subunits (Ref. 39 and see new analyses of
these data below).Moreover, others found that wild-type (WT)
UBE3A can stimulate Wnt pathway activation and protect
-catenin from proteasomal degradation with these activities
dependent on the ubiquitin ligase activity of UBE3A (40–42).
Recently, we characterized a de novo autism-linked
UBE3AT485A mutation that disrupts phosphorylation control
of UBE3A and enhances UBE3A ubiquitin ligase activity (6).
This UBE3AT485A mutation, along with an engineered
UBE3AT485E mutation that inhibits UBE3A by mimicking
phosphorylation, gave us newmolecular tools to probe the link
betweenUBE3A activity andWnt signaling. Through extensive
proteomic and functional experiments, we show that UBE3A
and Wnt signaling converge at the proteasome with UBE3A
impacting overall protein homeostasis, including -catenin
turnover, by ubiquitinating multiple proteasome subunits.
Intriguingly, subunits that interact with UBE3A and affectWnt
signaling are located along one side of the 19S regulatory parti-
cle, suggesting functional organization of the proteasome. The
UBE3AT485A mutant activated Wnt signaling more effectively
than WT UBE3A, and ligase-dead UBE3A failed to activate
Wnt signaling, raising the novel possibility that abnormal Wnt
signaling contributes to neurodevelopmental disorders involv-
ing UBE3A loss or gain of function.
Results
UBE3AT485A enhancesWnt signaling in a cell-context
dependentmanner
WT UBE3A, but not ligase-dead (LD)6 UBE3A, was found
previously to stimulate Wnt reporter gene expression in
HEK293T cells and to do so independently of Wnt ligand (40,
42). Given that a significant number of autism-linked de novo
mutations are found in genes associated with theWnt pathway
(14, 17), we sought to determine whether the autism-linked
UBE3AT485A mutation, which disables phosphorylation con-
trol and hyperactivates ubiquitin ligase activity (6), had an equal
or greater effect onWnt pathway activation. To test this possi-
bility, we transfected HEK293T cells with the -catenin-acti-
vated luciferase reporter (BAR) (43) along with the follow-
ing UBE3A expression constructs: WT UBE3A, UBE3A-LD,
UBE3AT485A, and UBE3AT485E (phosphomimetic mutant;
reduces UBE3A activity to near UBE3A-LD levels). We previ-
ously characterized the protein level and ubiquitin ligase activ-
ity of each construct in HEK293T cells (6). Cells were then
acutely (12–16 h) treated with control (L-cell) or Wnt3a-con-
ditioned medium (CM) prior to quantifying luciferase activity.
We found that WT UBE3A and the UBE3AT485A mutant
strongly stimulatedWnt pathway activation in the absence (Fig.
2A) or in the presence of Wnt ligand (Fig. 2B). The autism-
linked UBE3AT485A construct activated Wnt signaling to a
greater extent than WT UBE3A, particularly as the amount of
plasmid transfected was increased (Fig. 2C). The phosphomi-
metic UBE3AT485E mutant, which impairs UBE3A ubiquitin
ligase activity, was much less effective at stimulating Wnt
pathway activation. Consistent with a previous study (40),
UBE3A-LD did not activate the pathway (Fig. 2, A and B), indi-
cating that UBE3A ubiquitin ligase activity is required to
stimulate Wnt pathway activation. Lastly, we found that
UBE3AT485A stimulated Wnt pathway activation more than
11-fold (relative to T485E) in cells with low baselineWnt path-
way activation (L-cell control medium) and was relatively less
effective in cells treated acutely (12–16 h; 2.6-fold relative to
T485E) or chronically (one passage prior to transfection
through to lysis; 1.8-fold relative to T485E) with Wnt ligand
(Fig. 2D). These data suggest that UBE3A stimulates Wnt sig-
naling in a cell-context dependent manner and is relatively
more effective in cells with low levels of ongoingWnt signaling,
consistent with findings by Sherman and co-workers (42).
UBE3A and theWnt pathway converge at the proteasome
Epistasis experiments suggested that UBE3A stimulated the
Wnt pathway independently of GSK3 or adenomatous polyp-
osis coli protein (41).We performed additional epistasis exper-
iments, probing different parts of the pathway (Fig. 1), with the
O-acyltransferase inhibitor C59 (inhibits Wnt palmitoylation
and secretion), tankyrase inhibitor XAV939 (stabilizes the
destruction complex), GSK3 inhibitors CT99021 and LiCl,
the -catenin transcriptional activator valproic acid, and the
-catenin transcriptional inhibitor iCRT14 (supplemental Fig.
S1). These studies suggested thatUBE3A acts at or downstream
of the destruction complex and influences the transcriptional
activity of -catenin, consistent with work by Kuslansky
et al. (42).
We next sought to identify a molecular link between UBE3A
and theWnt/-catenin signaling pathway.Given thatUBE3A is
an E3 ubiquitin ligase that targets proteins for destruction, we
hypothesized that any proteins that 1) interact with UBE3A, 2)
are ubiquitinated by UBE3A, and 3) activate the Wnt pathway
6 The abbreviations used are: LD, ligase-dead; BAR, -catenin-activated lucif-
erase reporter; CM, conditionedmedium; SILAC, stable isotope labeling of
amino acids in cell culture; Ub, ubiquitin.
Figure 1. The canonical Wnt signaling pathway. Drugs used in epistasis
experiments are indicated (red). C59 is a porcupine inhibitor that suppresses
Wnt secretion, XAV939 is a tankyrase inhibitor that stabilizes the destruction
complex, LiCl and CT99021 are inhibitors of GSK3, valproic acid (VPA) is
an activator of -catenin-dependent transcription, and iCRT14 inhibits
-catenin-dependent transcription. TCF/LEF, T cell factor/lymphoid
enhancer factor; LRP, low-density lipoprotein receptor-related protein.
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when knocked down could represent bona fide UBE3A sub-
strates and serve as core components of this signaling pathway.
Published data sets addressed two of these criteria. Martínez-
Noël et al. (24) identified a comprehensive list of proteins that
selectively interact with UBE3A in HEK293T cells (relative to
NEDD4, another HECT domain E3 ubiquitin ligase). Of these
proteins, 63 interact with all three UBE3A isoforms (WT and
LD; Fig. 3A and supplemental Table S1).We recently identified
a comprehensive list of positive and negative regulators ofWnt
signaling in HEK293T cells from a near-saturation genome-
wide siRNA screen (39). Of these regulators, 1,958 proteins
significantly increased Wnt pathway activation when knocked
down (Fig. 3A and supplemental Table S2). Database for Anno-
tation, Visualization and Integrated Discovery (DAVID) analy-
sis predicted that “proteasome” was the top gene ontology term
for both protein lists (p  3  1054 and 8  108, respec-
tively). Remarkably, only 24 proteins were shared between
these two lists, and each of these proteins was a component of
the 19S regulatory particle, the 20S core complex, or a protea-
some accessory protein (Fig. 3B). Intriguingly, whenmapped to
the structure of the proteasome (44), the shared 19S regulatory
subunits were located on one side of the complex (Fig. 3C, red).
Subunits on the opposite side largely did not alterWnt pathway
signaling when knocked down (Fig. 3C, blue). These data sug-
gest that proteasome subunits are functionally organized with
one side of the 19S regulatory particle associated with Wnt/-
catenin signaling.
UBE3A physically associates with the proteasome (24–26),
and this association can be reversibly altered by certain stimuli
(23). To evaluate whether Thr-485 phosphorylation affects the
association of UBE3Awith the proteasome, we isolated UBE3A
protein complexes fromHEK293T cells overexpressing LD ver-
sions of UBE3AT485A, which cannot be phosphorylated, and
UBE3AT485E, a mutant that mimics phosphorylation. Using
mass spectrometry and spectral counts to quantify interactions,
we found that theUBE3AT485A andUBE3AT485Emutants inter-
act with the same proteasome subunits with a slight bias for
UBE3AT485A–proteasome subunit interactions (supplemental
Table S3 and supplemental Fig. S2A). To further evaluate
whether phosphorylation at Thr-485 affects UBE3A binding to
the proteasome, we biochemically purified proteasomes from
HEK293T cells expressing LD versions of UBE3AT485A and
UBE3AT485E mutants. UBE3A abundance was measured in
proteasome-bound and unbound fractions by Western blot
analysis. We found no difference between UBE3AT485A and
UBE3AT485E mutants, suggesting that phosphorylation does
not strongly influence UBE3A–proteosome interaction (sup-
plemental Fig. S2, B and C).
Figure 2. The autism-linked UBE3AT485A mutant exacerbatesWnt signaling. A and B, HEK293T cells were transfected with the BAR reporter, CMV-Renilla,
and empty vector or the indicated UBE3A plasmid. Cells were serum-deprived and treatedwith control (L-cell) CM (A) orWnt3a CM (B). Mean values are shown
for firefly:Renilla ratios (n  12). Error bars represent S.D. Statistical analysis was performed using one-way analysis of variance with Bonferroni post hoc
correction. ***, p 0.0005. C, HEK293T cells were transfectedwith increasing amounts of plasmid encodingWTUBE3A or UBE3AT485A. Mean values are shown
for firefly:Renilla ratios (n  3). Error bars represent S.D. Statistical analysis was performed using two-way analysis of variance with Bonferroni post hoc
correction. ***, p 0.0005. D, transfected HEK293T cells were grown for 12–16 h in L-cell CM or Wnt3a CM (acute) or in Wnt3a CM for one passage prior to
transfection through lysis (chronic). Values are shown as box and whisker plots for firefly:Renilla ratios (n 6).Whiskers represent the range of maximum and
minimum values obtained in our experiments. Statistical analysis was performed using a two-sample t test (two-tailed). *, p 0.05; ***, p 0.0005.
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Multiple proteasome subunits are ubiquitinated by UBE3A
We next sought to comprehensively identify proteins that
are ubiquitinated by UBE3A in HEK293T cells. We combined
quantitative stable isotope labeling of amino acids in cell cul-
ture (SILAC) with ubiquitin remnant immunoaffinity profiling
(45, 46). This approach allowed us to isolate ubiquitinated pep-
tides containing the characteristic diglycinemotif exposed after
tryptic digestion and to perform ratiometric analysis in cells
expressing active UBE3AT485A relative to inactive UBE3AT485E
(supplemental Table S4). We found that UBE3A ubiquitinated
multiple components of the proteasome, including eight core
proteasome subunits that physically interact with UBE3A and
that negatively regulateWnt signaling (Fig. 3B, shown in bold).
Of these eight subunits, we examined endogenous protein
abundance of five (PSMA2, PSMB1, PSMD2, PSMD4, and
PSMD11) by Western blot analysis in cells transfected with
UBE3AT485A or UBE3AT485E expression constructs. Protein
levels of most of these proteasome subunits were reduced in
UBE3AT485A-expressing cells relative to T485E controls in the
absence or presence ofWnt ligand (Fig. 4,A–C).We also exam-
ined endogenous levels of these five subunits in immortalized
human lymphocytes derived from theUBE3AT485A autismpro-
band and the unaffected (WT UBE3A) parents (47). We previ-
ously found that UBE3A ubiquitin ligase activity is elevated in
cells from this proband using PSMD4 (also known as S5A or
RPN10), RAD23A (HHR23A), and UBE3A as endogenous sub-
strates (6). Several proteasome subunits were reduced in cells
from the proband relative to the unaffected parents (Fig. 4, D
and E). Note that these lymphocytes showed no evidence of
Wnt pathway activation based on quantitative PCR experi-
mentswithWnt target genesAXIN2,BMP4,NKD1, and SOX17
(supplemental Fig. S3,A–D), likely because these non-adherent
cells have undetectable levels of-catenin protein (supplemen-
tal Fig. S3E). Thus, we could not evaluate the extent to which
endogenous Wnt signaling was affected in this patient-derived
cell line.
PSMD2 is a substrate of UBE3A
Our experiments suggested that PSMD2 (also known as
RPN1) was a novel UBE3A substrate. Unlike other 19S compo-
nents, PSMD2 is located at the edge of the regulatory complex
(Fig. 5A, green) and anchors several accessory proteins to the
proteasome (48). These accessory proteins include multiple
UBE3A substrates, RAD23A and RAD23B (28, 49), ADRM1,
PSMC3, UCHL5 (25), PSMD4 (6), and MCM7 (50), as well as
proteins that associate with UBE3A, including the E2 enzyme
UBE2L3 (51).
In titration experiments with increasing amounts of PSMD2
plasmid, we found that PSMD2 reduced UBE3AT485A-medi-
atedWnt pathway activation in the absence or presence ofWnt
ligand (Fig. 5, B andC). These findings suggest that overexpres-
sion of PSMD2 can functionally rescue or compensate for the
loss of endogenous PSMD2 in UBE3AT485A-expressing cells.
Moreover, high-molecular-weight ubiquitin-conjugated forms
of PSMD2 were detected in HEK293T cells expressing
UBE3AT485A, PSMD2, and HA-tagged ubiquitin after treat-
ment with the proteasome inhibitor MG-132 (30 M; 4 h) (Fig.
5D). In contrast, polyubiquitinated PSMD2was not detected in
cells expressing the inactive UBE3AT485E mutant (Fig. 5D). We
also performed in vitro ubiquitination reactions with recombi-
Figure 3. UBE3A and Wnt signaling converge at the proteasome. A, high-confidence unique UBE3A-interacting proteins identified by proteomics (63;
white) were cross-referenced with negative regulators of Wnt signaling identified from a genome-wide siRNA screen (1,958; red). The Venn diagram shows 24
common proteins (pink) that complex with UBE3A and negatively regulateWnt signaling. B, list of the 24 common proteins. Each protein was a component of
the 19S regulatory particle of the proteasome, the 20S core complex, or an accessory protein associated with the proteasome (Other). Proteins in bold were
identified as putativeUBE3A substrates fromubiquitin remnant immunoaffinity profiling (see supplemental Table S4).C, spatial organizationofWnt regulators
in the19Sproteasomecomplex. The cryo-EMstructure shows the19S and20Sproteasomecomplex (ProteinDataBank code5GJQ). 20S core complex subunits
are shown in gray. 19S subunits that negatively regulatedWnt signalingwhen knocked down in HEK293T cells are shown in red, whereas subunits that did not
affect Wnt signaling are shown in blue.
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nant ubiquitin, E1, E2, andUBE3A enzymes along with PSMD2
purified from HEK293T cells. A single distinct ubiquitin-con-
jugated PSMD2 species was detected in reactions containing
UBE3A (Fig. 5E) that differed from what was observed in cells
(Fig. 5D), suggesting that additional cellular factors promote
polyubiquitin chain formation on PSMD2. Collectively, these
data indicate that PSMD2 is a substrate of UBE3A and that
overexpression of PSMD2 dampensWnt pathway activation in
UBE3AT485A-expressing cells.
UBE3A regulatesWnt signaling throughmultiple proteasome
subunits
We next evaluated the extent to which additional protea-
somal subunits rescueWnt pathway activation inUBE3AT485A-
expressing cells. Plasmids encoding subunits that interact with
UBE3A were transfected into HEK293T cells together with
UBE3AT485A at 1:1 and 1:2 UBE3A:subunit ratios or alone to
confirm overexpression (supplemental Fig. S4). We were par-
ticularly interested in PSMD4 as PSMD4 is a well characterized
UBE3A substrate (6, 25, 26, 29). However, PSMD4 failed to
reduce Wnt pathway activation in UBE3AT485A-expressing
cells at the 1:1 or 1:2 transfection ratio (Fig. 6; ranked results
shown in supplemental Table S5). Instead, PSMD4 augmented
Wnt signaling by nearly 200% at the 1:2 transfection ratio. Of
the remaining subunits tested, PSMB1, PSMC2, PSMD2, and
PSMD7 consistently reduced Wnt pathway activation in
UBE3AT485A-expressing cells, whereas PSMC6 augmented the
Wnt response (at 1:1 and 1:2 ratios; Fig. 6 and supplemental
Table S5). PSMD2 was one of the most effective subunits to
rescue UBE3A-dependent Wnt activation in HEK293T cells
(supplemental Table S6). PSMD1, PSMD3, PSMD6, and
PSMD11 had no effect or inconsistent effects across the four
conditions. Our experiments collectively suggest that UBE3A
stimulates Wnt pathway activation by interacting with, ubiq-
uitinating, and reducing the levels ofmultiple (PSMB1, PSMC2,
PSMD2, and PSMD7) proteasome subunits.
UBE3A inhibits proteasome function and stabilizes-catenin
Several groups found that WT UBE3A inhibits the protea-
some in cells (25, 34). To determine whether UBE3AT485A sim-
ilarly affected proteasome activity, we transfected HEK293T
cells with UBE3AT485A or UBE3AT485E mutants along with a
Figure 4. UBE3AT485A depletes multiple endogenous proteasome subunits. A, protein lysates from HEK293T cells expressing UBE3AT485A or UBE3AT485E
mutants were analyzed byWestern blotting for proteasome subunit protein levels. Analysis was performed on cells grown in L-cell CM or Wnt3a CM. B and C,
quantification ofWestern blots for cells grown in L-cell CM (B) orWnt3a CM (C). Mean percent abundance values in UBE3AT485A samples relative to UBE3AT485E
samples are shown (n 6). Error bars indicate S.D. Statistical analysis was performed using a one-sample t test (two-tailed). *, p 0.05; **, p 0.005. PSMD11
was not analyzed due to its low abundance in HEK293T cells. D and E, representative Western blot (D) and quantification (E) of proteasome subunits in
immortalized lymphocyte cell lines fromthe father,mother, andautismproband (Simon’s SimplexCollection; Family ID13873).Meanpercent values are shown
relative to the father’s level (n 3). Error bars indicate S.D. *, p 0.05, one-sample t test.
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destabilized G76V-ubiquitin (UbG76V)-GFP fusion reporter
protein and mCherry as the normalization control. This
UbG76V-GFP construct was used previously to quantify protea-
some-dependent activity in cells (52). We found that the levels
of this UbG76V-GFP reporter were higher in cells transfected
with UBE3AT485A relative to the inactive T485E mutant, sug-
gesting that elevated UBE3AT485A activity inhibits proteasome
function in cells (Fig. 7, A and B). This difference in UbG76V-
GFP reporter levels was abolished in cells treated withMG-132
(10 M; 12 h; Fig. 7, A and B), further suggesting a proteasome-
dependent mechanism.
-Catenin is ubiquitinated and then degraded by the protea-
some, which limits entry to the nucleus and transcriptional
activity (Fig. 1). Given that UBE3AT485A reduces proteasome
activity, we hypothesized that nuclear-catenin levelsmight be
elevated in UBE3AT485A-expressing cells. Indeed, we found
that nuclear -catenin levels were slightly elevated in cells
expressing the UBE3AT485A mutant relative to cells expressing
UBE3AT485E in the absence or presence ofWnt ligand (Fig. 7,C
and D). Additionally, UBE3AT485A less effectively stimulated
Wnt signaling (relative to UBE3AT485E) in cells overexpressing
WT -catenin and did not augment Wnt signaling (relative to
UBE3AT485E) in cells overexpressing a constitutively active
-catenin construct (Fig. 7E). These data further demonstrate
that UBE3AT485A most effectively stimulates Wnt signaling in
cells with subsaturating levels of active -catenin, that is when
Figure 5. PSMD2 is a substrate of UBE3A. A, cryo-EM structure of the proteasome showing the location of PSMD2 (green) in the 19S regulatory particle
(Protein Data Bank code 5GJQ). B and C, PSMD2 dose-dependently rescues UBE3A-stimulatedWnt signaling. HEK293T cells were co-transfectedwith plasmids
encoding UBE3AT485A and increasing quantities of PSMD2 (0, 20, 40, and 60 ng). Cells were then grown in L-cell CM (B) or Wnt3a CM (C). Mean percent values
for firefly:Renilla ratios are shown relative to cells transfected with UBE3A empty vector (n 6). Error bars indicate S.D. ***, p 0.0005, one-sample t test
(two-tailed).D, HEK293Tcells transfectedwith the indicatedUBE3A,Myc-DDK-PSMD2, andHA-ubiquitin constructswere treatedwith theproteasome inhibitor
MG-132 (30M; 4 h). PSMD2was immunoprecipitated (IP) using an anti-FLAG antibody, and theWestern blot was probedwith an anti-HA antibody (left panel)
or PSMD2 antibody (right panels) to detect ubiquitinated PSMD2. E, an in vitro ubiquitin assay was performed using recombinant E1, E2 (UBE2D3), UBE3A, and
PSMD2 expressed and purified from HEK293T cells. Reactions were stopped at the indicated time, and the formation of ubiquitinated PSMD2 was monitored
using a PSMD2 antibody. WT UBE3A was omitted from the reaction as a negative control (first lane).
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baselineWnt pathway activation is low. Altogether, our results
suggest a mechanism whereby UBE3A ubiquitinates multiple
subunits of the proteasome, leading to impairment of protea-
some-mediated degradation of -catenin and increased
-catenin/Wnt signaling (Fig. 7F).
Discussion
Despite the well known association between excess UBE3A
and autism risk (4, 5, 53), including autism-linked mutations
that elevate UBE3A alone (6, 7), and extensive research on
UBE3A (10), it is currently unclear how excess UBE3A affects
mechanisms linked to autism and neurodevelopment. UBE3A
is thought to be a promiscuous enzyme (54), and this seeming
promiscuity has confounded attempts to identify the physio-
logical substrates ofUBE3A. Recently, we found that an autism-
linkedpointmutation inUBE3A (UBE3AT485A) disables a phos-
phorylation control switch and elevatesUBE3Aubiquitin ligase
activity (6). Here, we found that UBE3AT485A exacerbates Wnt
signaling by inhibiting the proteasome and stabilizing nuclear
-catenin. Numerous autism-linked genes are implicated in
Wnt signaling (14, 15, 17); valproic acid, an environmental risk
for autism, activatesWnt signaling (supplemental Fig. S1E) (55,
56); and Wnt signaling regulates proliferation and differentia-
tion of neuronal progenitors (57, 58). Our study and thework of
others (40–42) firmly place UBE3A within the Wnt signaling
pathway and provide fundamental new insights into how excess
UBE3A could impair brain development and increase risk for
autism.
Our biochemical and proteomics findings suggest that
UBE3A stimulates Wnt signaling by ubiquitinating multiple
proteasome subunits and reducing proteasome activity, which
ultimately stabilize -catenin. UBE3AT485A-mediated stimula-
tion of Wnt signaling was reduced in cells overexpressing dif-
ferent proteasome subunits, suggesting that proteasome sub-
units are functionally relevant UBE3A substrates. Multiple
laboratories have found that UBE3A can ubiquitinate protea-
some subunits and inhibit proteasome function (25, 34),
although one group found that UBE3A stimulated proteasome
proteolytic activity (27). Discrepancies could relate to differ-
ences in cell context or experimental approach. Jacobson et al.
(25) found that UBE3A inhibited the proteasome by in situ
ubiquitination provided the levels of polyubiquitinated pro-
teins in the cell were low. Cellular stresses that increase polyu-
biquitinated protein levels (oxidative stress and serum starva-
tion) blocked UBE3A from ubiquitinating the proteasome,
leading to increased proteasome activity (25). In a simplistic
sense, the proteasome can “sense” whether global polyubiquiti-
nated protein levels are low or high and, via UBE3A, adjust
Figure 6. Overexpression of proteasome subunits reversed the effect of UBE3AT485A onWnt signaling. A and B, BAR assays were performed in HEK293T
cells expressing theUBE3AT485Amutant and the indicated proteasome subunits. Cells were transfected using a 1:1 UBE3A:subunit ratio and grown in L-cell CM
(A) or Wnt3a CM (B). Values are shown as box andwhisker plots for percent firefly:Renilla ratios relative to cells transfected with UBE3AT458A empty vector. C
andD, cells were transfected using a 1:2 UBE3A:subunit ratio and grown in L-cell CM (C) orWnt3a CM (D). Values are shown as box andwhiskerplots for percent
firefly:Renilla ratios relative to cells transfected with UBE3AT458A  empty vector. A–D, n  9 (three independent experiments; three biological replicates/
experiment). *, p 0.05; **, p 0.005; ***, p 0.0005, one-sample t test (two-tailed).Whiskers represent the range ofmaximumandminimumvalues obtained
in our experiments.
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proteasomal activity accordingly. Thus, differences in cell cul-
ture conditions (such as differences in serum composition, oxy-
gen tension, and plating density) have the potential to influence
polyubiquitinated protein levels and alter proteasome activity
via UBE3A.
We found that knockdown of different proteasome sub-
units or overexpression of UBE3AT485A led to activation of
Wnt signaling in HEK293T cells, a cell line with low baseline
Wnt pathway activation. In contrast, UBE3AT485A was rela-
tively less effective at stimulatingWnt signaling in HEK293T
cells exposed (acutely or chronically) to Wnt ligand or in
HEK293T cells expressing elevated levels of-catenin. It is well
known that cell context can affect Wnt signaling (59, 60). Our
study suggests that the proteasome, which lies at the heart of
the Wnt signaling pathway (Fig. 1), and UBE3A, which regu-
lates proteasome function and subunit composition, can influ-
ence active -catenin levels in a cell context-dependent
manner.
This cell context-dependent effect of UBE3A has implica-
tions for brain development. Wnt signaling weakens over the
course of development in cortical neuron progenitors, which
express UBE3A biallelically (61), and varies by cell and tissue
type (62, 63). It is thus conceivable that cells with latent but low
levels of Wnt pathway activation may be more vulnerable to
UBE3A excess. Future experiments will be needed to test this
possibility.
To our knowledge, we are the first to identify a proteasomal
subdomain that associates with the Wnt signaling pathway.
Proteasome subunits that enhance Wnt signaling upon
siRNA-mediated knockdown localize to one side of the 19S
regulatory complex. Although this observation is based on data
from a primary siRNA screen andwill need to be independently
Figure 7. UBE3A inhibits the proteasome and increases nuclear -catenin accumulation. A and B, representative Western blot (A) and quantification (B)
of protein lysates from HEK293T cells expressing UBE3AT485A or UBE3AT485E, the destabilized UbG76V-GFP reporter protein, and mCherry as a transfection and
loading control. The proteasomewas inhibitedwithMG-132 (10M; 12 h).Mean percent values relative toUBE3AT458E-expressing cells are shown (n 5). Error
bars indicate S.D. *,p0.05, two-sample t test (two-tailed).C andD, representativeWesternblot (C) andquantification (D) of nuclear lysates fromHEK293T cells
expressingUBE3AT485AorUBE3AT485Emutants. Cellsweregrown in L-cell CMorWnt3aCMandanalyzed for-catenin abundance.Meanpercent values relative
to UBE3AT458E-expressing cells are shown (n 6). Error bars indicate S.D. *, p 0.05, two-sample t test (two-tailed). E, -catenin degradation is required for
UBE3A-dependent Wnt pathway activation. BAR assays were performed with HEK293T cells expressing UBE3AT485A or UBE3AT485E and co-transfected with
plasmids encoding GFP, WT -catenin, or a stabilized -catenin mutant. Values are shown as box and whisker plots for percent firefly:Renilla ratios relative to
cells transfected with GFP alone (n  9). Whiskers represent the range of maximum and minimum values obtained in our experiments. ***, p  0.0005,
two-sample t test (two-tailed). n.s., not significant. F, mechanism. Enhanced UBE3A activity at the proteasome reduces protein turnover, leading to -catenin
stabilization and enhanced transcription of Wnt target genes. TCF/LEF, T cell factor/lymphoid enhancer factor; LRP, low-density lipoprotein receptor-related
protein.
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verified, we speculate that such an arrangement could spatially
restrict docking or shuttling of Wnt pathway components to
the proteasome. The destruction complex scaffolding protein
AXIN1 can directly bind to -catenin and PSMD1, whereas
-catenin stabilization is dependent on its sequestration away
from the proteasome (64, 65). Post-translational modifications
of proteasome subunits, such as ubiquitination, could block the
association of-cateninwith the proteasome, whichwould sta-
bilize -catenin and promote Wnt signaling. Thus, cells might
physically segregateWnt signaling fromotherubiquitin-depen-
dent signaling pathways to permit independent control of cel-
lular processes that depend on proteasomal proteolysis.
Numerous pathways require protein degradation, but it has
long remained unknown how the proteasome simultaneously
processes signaling components to maintain homeostasis. Our
study raises the possibility that distinct pathways are compart-
mentalized at the proteasome, and this provides the necessary
molecular platforms to execute multiple parallel functions.
Lastly, our study has broader implications and suggests that
UBE3A could affect additional proteins, signaling pathways,
and cellular functions that are particularly sensitive to ubiquiti-
nation and proteasomal degradation. Our findings hint that the
apparent promiscuity of UBE3A may relate to its inhibitory
effect on the proteasome as proteasome inhibition would ele-
vate the levels of many ubiquitinated proteins, including those
that are not direct UBE3A substrates.
Experimental procedures
Molecular biology
All UBE3A constructs used in this study were derived
from human UBE3A isoform II (NCBI accession number
NP_000453.2).Myc epitope tagswere placed on theN terminus
of UBE3A by polymerase chain reaction and cloned into pCIG2
using SacI and XmaI or into pEGFP-N1 using BamHI andNotI.
All constructs were verified by sequencing. HA-tagged ubiqui-
tin, pGL3-BAR, TK-Renilla, pHAGE -catenin WT, and
pHAGE -catenin mutant constructs were described previ-
ously (39, 66, 67). UbG76V-GFP was obtained from Addgene
(23969). pCMV6 Myc-DDK-tagged constructs for PSMB1
(RC201798), PSMC2 (RC200945), PSMC5 (RC201251),
PSMC6 (RC202809), PSMD1 (RC210486), PSMD2 (RC203204),
PSMD3 (RC202307), PSMD6 (RC202292), PSMD7 (RC203133),
PSMD11 (RC201201), and untagged PSMD4 (SC111678) were all
purchased fromOrigene.
Antibodies and reagents
Primary antibodies used were mouse anti-Myc (1:1,000;
EMD Millipore, 05-724), mouse anti-HA (1:1,000; EMD
Millipore, 05-904), rabbit anti-GAPDH (1:1,000; Genetex,
GTX100118), mouse anti-FLAG M2 (1:1,000; Sigma, F3165),
rabbit anti-PSMA2 (1:1,000; Thermo Fisher, PA5-17294), rab-
bit anti-PSMB1 (1:1,000; Thermo Fisher, PA5-49648), rabbit
anti-PSMD2 (1:1,000; Thermo Fisher, PA5-27663), goat anti-
PSMD4 (1:1000; Boston Biochem, AF5540), rabbit anti-
PSMD11 (1:1,000; Thermo Fisher, PA5-27447); mouse
anti-GFP (1:5,000; Clontech, 632281), rabbit anti-mCherry
(1:2,500; Abcam, ab167453), rabbit anti--catenin (1:1,000,
Cell Signaling Technology, 9562), and mouse anti-HDAC1
(1:1,000; Cell Signaling Technology, 5356). LiCl, XAV939,
iCRT14, and valproic acid were purchased from Sigma;
CT99021 was purchased from Axon Med Chem; and C59 was
purchased from Cellagen Technology. MG-132 was purchased
from Calbiochem. Wnt3a medium was made according to the
ATCC protocol (68).
Tissue culture
HEK293T cells (ATCC) were maintained in a 5% CO2
humidified incubator in DMEM (Thermo Fisher) containing
4.5 g/liter glucose, 584 mg/liter glutamine, and 110 mg/liter
sodium pyruvate supplemented with 10% (v/v) fetal bovine
serum (Hyclone) and 1 antibiotic-antimycotic (penicillin,
streptomycin, amphotericin B; Life Technologies). For bio-
chemical analyses, transfections were performed in 6-well
dishes using Lipofectamine 2000 (Life Technologies) according
to the manufacturer’s instructions. HEK293T cells were lysed
in NuPAGE lithium dodecyl sulfate sample buffer (Life Tech-
nologies) supplemented with 1% -mercaptoethanol and 1
CompleteMini protease inhibitor mixture (Roche Applied Sci-
ence). Lysates were boiled, and proteins were resolved by
4–20% SDS-PAGE and transferred to nitrocellulose mem-
branes (Bio-Rad). Membranes were blocked in Odyssey block-
ing buffer (LI-COR Biosciences) and probed with the appropri-
ate primary antibodies overnight. Protein bandswere visualized
using the Odyssey CLx infrared imaging system (LI-COR Bio-
sciences) with the following secondary antibodies: donkey anti-
rabbit 800CW (926-32213), donkey anti-rabbit 680RD (925-
68073), and donkey anti-mouse 680RD (926-68072; all from
LI-COR Biosciences and used at 1:10,000). Nuclear fraction-
ation was performed using the NE-PER kit (Thermo Fisher)
according to the manufacturer’s instructions.
Immortalized human lymphocytes (Simons Simplex Collec-
tion) were maintained in a 5% CO2 humidified incubator in
RPMI 1640 medium supplemented with 15% (v/v) fetal bovine
serum (Hyclone), 1 GlutaMAX (Gibco), and 1 antibiotic-
antimycotic. The following cell lines were used for our study:
13873.Fa, 13873.Mo, and 13873.P1. For protein analysis, 10
million lymphocytes were collected by centrifugation and lysed
for 20 min on ice with periodic rocking in a lysis buffer consist-
ing of 20 mMHEPES, pH 7.4, 1% Nonidet P-40, and 50 mM KCl
supplemented with protease and phosphatase inhibitors. Sam-
ples were cleared at 1,000  g for 5 min, and the supernatant
was collected and subjected to a protein assay (Bio-Rad) to
determine concentration. Samples were prepared by diluting in
sample buffer supplemented with 1% -mercaptoethanol,
boiled, and resolved by SDS-PAGE.
Luciferase assays
BAR assays were performed in 96-well plates for all experi-
ments except those shown in supplemental Fig. S1, B–F (see
below). HEK293T cells were plated at a density of 10,000/well.
Cells were transiently transfected with 10 ng of pRL-TK-Re-
nilla, 30 ng of BAR-pGL3, and 60 or 80 ng of the indicated
constructs using the TransIT-2020 transfection reagent
(Mirus) orTransIT-LT1 transfection reagent (Mirus). After 2 h,
medium containing transfection reagents was replaced with
fresh medium. The following day, cells were serum-deprived
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(0.2% FBS) for 6 h and stimulated with Wnt3a-conditioned
medium or control L-cell medium for 12–16 h. Reporter gene
expression was assessed using the Dual-Luciferase reporter
assay system (Promega) and measured on an Enspire plate
reader from PerkinElmer Life Sciences. For supplemental Fig.
S1,B–F, HEK293T cells were plated at a density of 5,000/well in
384-well plates, and drugswere added 4 h postplating. 24 h after
plating, cells were transfected with 5 ng of pRL-TK-Renilla, 15
ng of BAR-pGL3, and 30 ng of the indicated UBE3A expression
constructs using FuGENE HD (Promega). Reporter gene
expression was assessed 24 h post-transfection using the Dual-
Glo luciferase assay system (Promega). For all experiments, the
luciferase activity was normalized against Renilla activity.
Ubiquitin remnant immunoaffinity profiling
HEK293T cells were grown in high-glucose DMEM (Caisson
Laboratories) supplementedwith 10%dialyzed FBS (Gibco), 3.7
g/liter sodium bicarbonate, 1 GlutaMAX, and 1 antibiotic-
antimycotic. For heavy medium, 50 g/ml L-lysine (Lys8) and
40 g/ml L-arginine (Arg10) were added (Cambridge Isotope
Laboratories). 50 g/ml standard L-lysine and 40 g/ml stan-
dard L-arginine (Thermo Fisher) were added for light medium.
For complete labeling, cells were passaged for at least seven
generations in the above medium. Cells were lysed in lysis
buffer (8 M urea in 50mMTris-HCl, pH 7.5, 150mMNaCl, 1mM
EDTA, 2 g/ml aprotinin, 10 g/ml leupeptin, 1 mM PMSF, 50
M PR-619, and 1 mM iodoacetamide) and sonicated to clarify
the lysate. The extract was centrifuged at 20,000 rpm at 4 °C for
15 min, and protein was estimated using the method of Brad-
ford (69). Both heavy and light protein samples were mixed in
1:1 ratio (mg:mg) and diluted in 50 mM Tris-HCl, pH 7.5, to
reduce the urea concentration to 2 M. The total protein was
digested overnight with sequencing grade trypsin (Promega).
The trypsin:protein ratio was maintained at 1:100. Total pep-
tides were purified on a Sep-Pak column (Waters) and eluted
with a 40-ml step gradient of 10–50% acetonitrile and 0.1%
trifluoroacetic acid gradient (10, 15, 20, 25, 30, 35, 40 and 50%;
5 ml each). The eluent fractions were lyophilized overnight
until dry powdery flakes were obtained.
A diglycine antibody kit was purchased from Cell Signaling
Technology (PTMScan Ubiquitin Remnant Motif (K--GG)
kit 5562). Dried total cell peptide samples were solubilized in
1 immunoaffinity purification buffer, and peptide immuno-
precipitations were performed at 4 °C for 4–6 h. The bead
slurry was washed three times with PBS and two times with
water. K--GGpeptides were elutedwith twowashes of 50l of
0.15% trifluoroacetic acid (TFA). Eluted peptides were further
purified on PierceC18 spin columns (Cat 89870) using theman-
ufacturer’s protocol. Peptides were eluted using 70% acetoni-
trile and 0.1%TFA solution in 50-l volumes twice and dried in
a SpeedVac at room temperature.
Mass spectrometry
Mass spectrometry analysis was performed at the Michael
Hooker Proteomics Center at the University of North Carolina.
Dried peptide samples were reconstituted in 1% acetonitrile
and 0.1% formic acid. Each sample was analyzed by LC/MS/MS
using an Easy nLC 1000 coupled to a QExactive HF mass spec-
trometer (Thermo Scientific). Samples were injected onto an
Easy Spray PepMap C18 column (75-m inner diameter  25
cm; 2-mparticle size) (Thermo Scientific) and separated over
a 2-h method. The gradient for separation consisted of 5–35%
mobile phase B at a 250 nl/min flow rate where mobile phase A
was 0.1% formic acid in water and mobile phase B consisted of
0.1% formic acid in acetonitrile. The QExactive HF was oper-
ated in data-dependent mode where the 15 most intense pre-
cursors were selected for subsequent fragmentation. Resolu-
tion for the precursor scan (m/z 400–1600) was set to 120,000
with a target value of 3 106 ions. MS/MS scan resolution was
set to 30,000with a target value of 1 105 ions. The normalized
collision energy was set to 27% for higher-energy collisional
dissociation, and the isolation window was set to 1.6m/z. Pep-
tide match was set to preferred, and precursors with unknown
charge or charge states of 1 and7 were excluded.
Raw data files were processed using Proteome Discoverer
version 2.1 (Thermo Scientific). Peak lists were searched
against a reviewed humanUniProt database (containing 20,203
entries), appendedwith a contaminant database, using Sequest.
The following parameters were used to identify tryptic peptides
for protein identification: 10-ppm precursor ion mass toler-
ance; 0.02-Da product ion mass tolerance; up to two missed
trypsin cleavage sites; carbamidomethylation of Cyswas set as a
fixed modification; and oxidation of Met, Gly-Gly of Lys, phos-
phorylation of Ser/Thr/Tyr, [13C6]Arg, [13C6]Lys, and acetyla-
tion of the N terminus were set as variable modifications. Per-
colator was used to estimate the number of false-positive
identifications, and a q-value (false discovery rate) was
assigned, a q-value of0.05 (5% false discovery rate), whichwas
used to filter all results. The ptmRS node was used to assign the
post-translational modification site localization probability.
Peptide quantitationwas enabled to determine SILAC ratios for
ubiquitin-modified peptides.
Ubiquitination assays
In vitro ubiquitination assays were performed using immu-
nopurified PSMD2 in combination with a commercially avail-
able recombinant UBE3A ubiquitin ligase kit (Boston Biochem,
K-230) according to the manufacturer’s instructions. In brief,
HEK293T cells grown in 25-cm dishes were transfected with a
plasmid encoding Myc-DDK-PSMD2 and allowed to grow for
48 h. Cells were lysed on ice for 20 min with gentle agitation
using an immunoprecipitation buffer containing 20 mM
HEPES, pH 7.4, 1% Nonidet P-40, 50 mM KCl, and 100 mM
NaCl. Lysates were clear by centrifugation, and PSMD2 was
immunoprecipitated using an anti-Myc affinity gel (Sigma,
A7470) at 4 °C for 2 h. The resulting beads were washed two
times each (eight washes total) in immunoprecipitation buffer
containing 100, 250, and 500 mM NaCl as well as two final
washes in PBS. PSMD2 was eluted from the beads in PBS con-
taining 10 g/ml Myc peptide (Sigma).
For cell-based assays, HEK293T cells were transfected with
constructs encoding UBE3A, Myc-DDK-PSMD2, and HA-
ubiquitin. Cells were allowed to grow for 48 h and treated with
30 M MG-132 for 4 h. The cells were then lysed in radioim-
mune precipitation assay buffer containing 1% SDS and 30 M
MG-132. Cell lysates were boiled for 20 min and clarified by
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centrifugation at 15,000 g for 10 min. The resulting superna-
tantwas diluted 1:10 (v/v) in an immunoprecipitation buffer (20
mM HEPES, pH 7.4, 50 mM KCl, and 1% Triton X-100), and
PSMD2 was immunoprecipitated using the EZ View anti-
FLAG affinity gel (Sigma, F2426) at 4 °C for 1 h. The final com-
plex was washed three times with immunoprecipitation buffer
containing 125 mM NaCl, resuspended in sample buffer, and
processed for SDS-PAGE and immunoblot analysis.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software. Statistical treatments for each experiment are indi-
cated in the figure legends. p 0.05 was considered significant.
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Note added in proof—In the version of the article that was published
as a Paper in Press on May 30, 2017, the PSMA2 and PSMB1 immu-
noblots shown in Fig. 4Dwere derived from the same physical mem-
brane. As these two proteins are the same size, the two images
appeared to be similar. To avoid any confusion, the PSMB1 immu-
noblot was replaced using an image from a replicate immunoblot.
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